Adam Gault H.C. Wainwright started coverage of Arcus Biosciences ( NYSE: RCUS ) with a neutral rating, citing reservations about upcoming data.
The bank said it doesn’t expect casdatifan ARC-20 data due later this month and domvanalimab data from ARC-10 “to be largely differentiated from competitors.”.